Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients

Marie Sandström(Uppsala University Hospital), Mats O. Karlsson(Uppsala University), Peter Nygren(Uppsala University), Mattias Johansson(Centre international de recherche sur le cancer), Henrik Lindman(Uppsala University), Jonas Bergh(Karolinska Institutet)
Cancer Chemotherapy and Pharmacology
February 7, 2006
10.1007/s00280-005-0140-2
Cited by 67

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k